Immunoglobulin constant region fc receptor binding agents
AssigneesUniversity of Maryland, Baltimore, Gliknik Inc.
InventorsScott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
Life of this patent
Estimating the term…
Abstract
IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
Claims19
-20. (canceled)
A method of treating an autoimmune or inflammatory disease comprising administering to a subject in need thereof a composition comprising a cluster stradomer comprising at least two multimerized cluster stradomer units,
- wherein each of said cluster stradomer units comprises at least one multimerizing region selected from an IgG2 hinge or an isoleucine zipper and at least one Fc domain comprising a CH2 domain and a CH3 domain from IgG1 or IgG3 or a combination thereof,
- wherein the multimerizing region(s) of the at least two cluster stradomer units multimerize to form the cluster stradomer, and
- wherein the cluster stradomer is capable of specifically binding to at least two Fc receptors.
A method of treating an autoimmune or inflammatory disease comprising administering to a subject in need thereof a composition comprising a cluster stradomer comprising at least two multimerized cluster stradomer units,
- wherein each of said cluster stradomer units comprises an IgG2 hinge multimerizing region and an IgG1 Fc domain comprising a CH2 and CH3 domain,
- wherein the IgG2 hinge multimerizing region of the at least two cluster stradomer units multimerize to form the cluster stradomer, and
- wherein the cluster stradomer is capable of specifically binding to at least two Fcγ receptors.
A method of treating an autoimmune or inflammatory disease comprising administering to a subject in need thereof a composition comprising a cluster stradomer comprising at least two multimerized cluster stradomer units,
- wherein each of said cluster stradomer units comprises an IgG2 hinge multimerizing region and an IgG3 Fc domain comprising a CH2 and CH3 domain,
- wherein the IgG2 hinge multimerizing region of each of the at least two cluster stradomer units multimerize to form the cluster stradomer, and
- wherein the cluster stradomer is capable of specifically binding to at least two Fcγ receptors.
Dependencies are inferred from the claim text.